<DOC>
	<DOCNO>NCT01772251</DOCNO>
	<brief_summary>Diabetes mellitus ( DM ) chronic disease carbohydrate , fat , protein metabolism cause absolute relative deficiency insulin , anabolic hormone . The current method insulin therapy diabetic patient multiple daily injection therapy continuous subcutaneous insulin infusion external pump . This rout administration may lead hyperinsulinemia insulin administer non physiological way , target mainly extra hepatic tissue ( muscle , fat ) . A method provide insulin without need injection goal drug delivery . Oshadi Drug Administration Ltd. develop oral carrier protein base biochemistry quantum theory biochemical reaction . The carrier enable absorption protein gastrointestinal tract full structure . Oshadi also develop Oshadi Icp - insulin , proinsulin C-peptide Oshadi carrier , administrate orally . This study design order evaluate safety feasibility multiple administration Oshadi Icp</brief_summary>
	<brief_title>Safety Tolerability Oshadi Icp In Patients With Type 1 Diabetes Mellitus - Phase Ib Clinical Study</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<criteria>Type 1 diabetes mellitus ( accord ADA criterion ) 1 year . Male/female 18 year old old . BMI≥18.5 ≤25 Female childbearing age must commit avoid pregnancy use contraception study . Patients must understand willing give write informed consent prior study procedure evaluation willing adhere study schedule requirement . Any history significant cardiac , renal , neurologic , metabolic , pulmonary , gastrointestinal , hematologic abnormality , chronic hepatic disease disease judgment investigator would interfere study confound result . Symptomatic DKA last 6 month Patients positive HIV HCV serology positive HBsAg screening . History evidence active liver disease . History epilepsy . One hypoglycemic seizure episode last six month one hypoglycemic seizure episode last year . History sever recurrent hypoglycemic unawareness . Cpeptide &gt; 3 mg/ml ( fast ) Total average daily insulin dosage ≥1 IU/kg body weight . Polycystic ovary syndrome Acanthosis nigricans 6.5 % &gt; HbA1c HbA1c &gt; 10 % eGFR &lt; 60 . Female patient breastfeed positive pregnancy test screening time study willing practice birth control study period . Inability give write informed consent History alcohol drug abuse within 6 month screen . Patients positive urine drug screen substance abuse ( benzodiazepine , THC , opiates , amphetamine , cocaine ) screening . Mental disorder . Patients poor venous access Significant swallowing disorder Digestive disorder Small bowel surgery Any intercurrent disease last week prior screen judgment investigator might affect blood glucose level . Any infectious disease develop 4 week prior study . Malabsorption disorder . Any significant abnormality principal investigator baseline laboratory evaluation : liver kidney function , electrolyte , albumin , lipase , TSH , hemoglobin , white blood cell count differential , platelet .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2013</verification_date>
	<keyword>Diabetes Mellitus</keyword>
	<keyword>Oral Insulin</keyword>
</DOC>